Investing.comCodex · 实盘不做把握 8/10
北京时间·🕒 发布 19:04:44时区推断·⟳ 抓取 19:09:10·⚡ 决策 08-04 23:00:41 +3h51m·84.2 天前
CAMP4完成此前已宣布私募融资第二批交割，获约5010万美元推进CMP-002
本条只是此前已宣布私募融资的第二批交割，核心条款与资金用途没有新的超预期增量。
📄 原文Investing.com↗ 原文
CAMP4 closes $50.1 million second tranche of private placement
U.S.-Iran talks uncertain; Palantir, Snap report - what’s moving markets CAMBRIDGE, Mass. - CAMP4 Therapeutics Corporat…
不做 CAMP4 Therapeutics（CAMP.US）
同一具体催化已在已处理消息库命中：CAMP4完成此前已宣布私募融资第二批交割的IR/wire/8-K版本均已处理；本条为Investing.com重复转述，且融资交割本身没有新的临床或商业化超预期增量，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-04 · 扩散 medium · price-in 风险 high ↗
关键理由
- 本条只是此前已宣布私募融资的第二批交割，核心条款与资金用途没有新的超预期增量。
- 已处理消息库在同一时间段命中同一具体催化，重复转述不应再次出卡或建仓。
主要风险
- 私募带来现金补充但同时形成股本摊薄，且融资事件本身不等于临床或商业化价值重估。
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 2,276 字
U.S.-Iran talks uncertain; Palantir, Snap report - what’s moving markets
CAMBRIDGE, Mass. - CAMP4 Therapeutics Corporation (NASDAQ:CAMP) announced today the closing of the second tranche of a private placement initially disclosed on September 9, 2025, raising approximately $50.1 million in gross proceeds.
The clinical-stage biopharmaceutical company issued 10,756,498 shares of common stock at $1.53 per share, 39,306 shares at $1.65 to certain directors, employees and consultants, and 21,925,368 pre-funded warrants priced at $1.5299 each, according to a press release statement.
The company stated it intends to use the net proceeds to support advancement of CMP-002, its investigational antisense oligonucleotide therapeutic candidate for SYNGAP1-related disorder. CAMP4 recently received clearance from Australia’s Therapeutic Goods Administration and local Human Research Ethics Committee to initiate a Phase 1/2 clinical trial for the treatment. Funds will also support development of the company’s early-stage pipeline.
Investors participating in the second closing include Coastlands Capital, Janus Henderson Investors, Balyasny Asset Management, Vivo Capital, 5AM Ventures, Adage Capital Management LP, Trails Edge Capital Partners and CURE SYNGAP1.
Leerink Partners served as lead placement agent for the transaction, with Piper Sandler & Co., Cantor Fitzgerald & Co. and Wedbush Securities Inc. acting as co-placement agents.
The securities were sold in a transaction not involving a public offering and were not registered under the Securities Act of 1933. The company granted customary resale registration rights for shares of common stock issuable upon exercise of the pre-funded warrants.
CAMP4 develops regulatory RNA-targeting therapeutics designed to upregulate gene expression. CMP-002 is designed to bind to a SYNGAP1-specific regulatory RNA to increase SYNGAP1 gene expression.
SYNGAP1-related disorder is a rare central nervous system disorder affecting over 10,000 individuals in the United States. The condition is characterized by intellectual disability in all patients, with no currently approved disease-modifying therapies available.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
CAMBRIDGE, Mass. - CAMP4 Therapeutics Corporation (NASDAQ:CAMP) announced today the closing of the second tranche of a private placement initially disclosed on September 9, 2025, raising approximately $50.1 million in gross proceeds.
The clinical-stage biopharmaceutical company issued 10,756,498 shares of common stock at $1.53 per share, 39,306 shares at $1.65 to certain directors, employees and consultants, and 21,925,368 pre-funded warrants priced at $1.5299 each, according to a press release statement.
The company stated it intends to use the net proceeds to support advancement of CMP-002, its investigational antisense oligonucleotide therapeutic candidate for SYNGAP1-related disorder. CAMP4 recently received clearance from Australia’s Therapeutic Goods Administration and local Human Research Ethics Committee to initiate a Phase 1/2 clinical trial for the treatment. Funds will also support development of the company’s early-stage pipeline.
Investors participating in the second closing include Coastlands Capital, Janus Henderson Investors, Balyasny Asset Management, Vivo Capital, 5AM Ventures, Adage Capital Management LP, Trails Edge Capital Partners and CURE SYNGAP1.
Leerink Partners served as lead placement agent for the transaction, with Piper Sandler & Co., Cantor Fitzgerald & Co. and Wedbush Securities Inc. acting as co-placement agents.
The securities were sold in a transaction not involving a public offering and were not registered under the Securities Act of 1933. The company granted customary resale registration rights for shares of common stock issuable upon exercise of the pre-funded warrants.
CAMP4 develops regulatory RNA-targeting therapeutics designed to upregulate gene expression. CMP-002 is designed to bind to a SYNGAP1-specific regulatory RNA to increase SYNGAP1 gene expression.
SYNGAP1-related disorder is a rare central nervous system disorder affecting over 10,000 individuals in the United States. The condition is characterized by intellectual disability in all patients, with no currently approved disease-modifying therapies available.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。